Ferric carboxymaltose (Ferinject®) associated hypophosphataemia: case report illustrating the need for increased awareness to minimise incidence and risk

Fisher, Stacey and Jonker, Leon ORCID: https://orcid.org/0000-0001-5867-4663 (2020) Ferric carboxymaltose (Ferinject®) associated hypophosphataemia: case report illustrating the need for increased awareness to minimise incidence and risk. Acute Medicine Journal, 19 (2). pp. 102-105.

Preview

PDF - Accepted Version Available under License CC BY-NC-ND Download (230kB) | Preview

Abstract

Ferric carboxymaltose (Ferinject®) is an infusion administered for the treatment of iron deficiency anaemia. A number of previous case reports have shown the occurrence of hypophosphataemia after Ferinject® treatment, supposedly managed though high dose phosphate therapy. This case report highlights the risk associated with, and futility of, managing this adverse effect through high dose phosphate infusion. A review of the available literature suggests that if hypophosphataemia develops as a result of Ferinject®, through upregulation of the renal protein Fibroblast Growth Factor-23, it cannot be readily reversed and on average persists for circa 50 days. Acute medical units should be aware of this – likely underreported – adverse effect, and avoid treating these hypophosphataemic patients with high dose phosphate since it can compound symptoms.

Item Type:	Article
Journal / Publication Title:	Acute Medicine Journal
Publisher:	Rila Publishing
ISSN:	1747-4892
Departments:	Institute of Health > Medical Sciences
Additional Information:	PMID: 32840261
Depositing User:	Christian Stretton
Date Deposited:	26 Aug 2020 12:27
Last Modified:	13 Jan 2024 11:01
URI:	https://insight.cumbria.ac.uk/id/eprint/5669

Downloads